Rituximab for the treatment of immune-mediated glomerular diseases
10.16571/j.cnki.1008-8199.2015.11.021
- VernacularTitle:利妥昔单抗在治疗免疫介导的肾小球肾炎中的应用
- Author:
Ling JIANG
;
Shijun LI
- Publication Type:Journal Article
- Keywords:
Rituximab;
Glomerular diseases;
Immune-mediated diseases;
Lupus nephritis
- From:
Journal of Medical Postgraduates
2015;(11):1204-1208
- CountryChina
- Language:Chinese
-
Abstract:
Rituximab ( RTX) is a monoclonal antibody to the CD 20 antigen on B-cells that was initially designed and approved for the treatment of non-Hodgkin′s B-cell lymphoma and has emerged as a potent immunosuppressant for many immune -mediated disea-ses.Given its efficacy , tolerability and safety profile in comparison to more conventional treatment regimens , RTX is rapidly emerging as a critical therapeutic modality for glomerular disease .The paper reviews the role of RTX in the treatment of ANCA-associated vascul-itis, lupus nephritis , mixed cryoglobulinemia , membranous nephropathy , minimal change disease , and focal segmental glomeruloscle-rosis.
